References
- Mustard JF, Packham MA, Kinlough-Rathbone RL. Mechanisms in thrombosis. Haematosis and Thrombosis, AL Bloom, DP Thomas. Churchill Livingstone, London 1981; 503–26
- Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci, USA 1975; 72: 2994–8
- Johnson RA, Morton DR, Kinner JH, Gorman RR, McGuire JC, Sun FF, Whittaker N, Bunting S, Salmon J, Moncada S, Vane JR. The chemical structure of prostaglandin X (prostacyclin). Prostaglandins 1976; 12: 915–29
- Vesterqvist O, Gréen K, Johnsson H. Thromboxane and prostacyclin formation in patients with deep vein thrombosis. Thromb Res 1987; 45: 393–402
- FitzGerald GA, Pedersen AK, Patrano C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67: 1174–7
- Roberts LJ, Sweetman BJ, Oates JA. Metabolism of thromboxane B2 in man—identification of twenty urinary metabolites. J Biol Chem 1981; 256: 8384–93
- Rosenkrantz B, Fischer C, Weimer KE, Frölich JC. Metabolism of prostacyclin and 6-keto-prosta-glandin F1α in man. J Biol Chem 1980; 255: 10194–8
- Gréen K, Vesterqvist O. In vivo synthesis of thromboxane and prostacyclin in man in health and disease. Data from measurements of major urinary metabolites, U Zor, Z Naor, FI Kohen. Raven Press, New York 1986; 309–24, In: Advances in Prostaglandin, Thromboxane and Leukotriene Res. Vol 16.–
- Vesterqvist O, Gréen K, Lincoln FH, Sebek OK. Development of a GC-MS method for quantitation of 2, 3-dinor-TxB2 and determinations of the daily urinary excretion rates in healthy humans. Thromb Res 1983; 33: 39–49
- Vesterqvist O, Gréen K. Development of a GC-MS method for quantitation of 2, 3-dinor-6-keto-PGF1α and determination of the urinary excretion rates in healthy humans under normal conditions and following drugs. Prostaglandins 1984; 28: 139–54
- Vesterqvist O, Gréen K. Urinary excretion of 2, 3-dinor-thromboxane B2 in man under normal conditions, following drugs and during some pathological conditions. Prostaglandins 1984; 27: 627–44
- Vesterqvist O. Rapid recovery of in vivo prostacyclin formation after inhibition by aspirin—Evidence from measurements of the major urinary metabolite of prostacyclin by GC-MS. Eur J Clin Pharm 1986; 30: 69–73
- Henriksson P, Wennmalm Å, Edhag O, Vesterqvist O, Gréen K. In vivo production of prostacyclin and thromboxane in patients with acute myocardial infarction. Br Heart J 1986; 55: 543–8
- Schött U, Thorén T, Sjöstrand U, Berséus O, Söderholm B. Three per cent dextran-60 as a plasma substitute in blood component therapy. Acta Anaesthesiol Scand 1985; 29: 775–81
- Rosenkranz B, Frölich JC. Problems of assessment of prostacyclin formation in vivo. Prostaglandins 1984; 27: 655–7
- Forder RA, Carey F. Measurements of human venous plasma prostacyclin and metabolites by radioimmunoassay: A reappraisal. Prostaglandins, Leukotrienes Med 1983; 12: 323–346
- FitzGerald GA, Brash AR, Falardeau P, Oates JA. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest 1981; 68: 1272–6
- Patrano C, Ciabattoni G, Pugliese F, Pierucci A, Blair JA, FitzGerald GA. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 1986; 77: 590–4
- Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase of oral aspirin. J Clin Invest 1978; 61: 314–9
- Nicolaides AN. Prevention of deep vein thrombosis. Geriatrics 1973; 28: 69
- Vesterqvist O, Gréen K, Lewin J, Swedenborg J. Synthetic arterial grafts cause prolonged increase in the in vivo formation of thromboxane and prostacyclin in humans. Res Exp Med 1987; 187: 175–84
- Henny CP, Odoom JA, Ten Cate H, Ten Cate JW, Oosterhoff RJF, Dabhoiwala NF, Sih JL. Effects of extradural bupivacaine on the haemostatic system. Br J Anaesth 1986; 58: 301–5
- Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, DeSanctis RW. Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med 1977; 297: 1246–9
- Alfaro MJ, Páramo JA, Rocha E. Prophylaxis of thromboembolic disease and platelet-related changes following total hip replacement: A comparative study of aspirin and heparin-dihydroergotamine. Thromb Haemostas 1986; 56: 53–6